+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs

Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs

American Journal of Translational Research 3(2): 166-179

Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells. Recently, their use has been clinically validated in cancer patients resulting in the approval of two HDAC inhibitors, vorinostat and depsipetide, by the FDA. Also, clinical trials of several HDAC inhibitors for use as anti-cancer drugs (alone or in combination with other anti-cancer therapeutics) are ongoing. However, the molecular mechanisms underlying the response to HDAC inhibitors in cancer patients are not fully understood. In this review, we summarize our understanding of the molecular and biological events that underpin the anticancer effects of HDAC inhibitors and the outcomes of recent clinical trials involving these drugs.

(PDF emailed within 1 workday: $29.90)

Accession: 053566308

Download citation: RISBibTeXText

PMID: 21416059

Related references

Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. Therapeutic Advances in Urology 7(6): 388-395, 2015

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Journal of Hematology and Oncology 3: 5, 2010

Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26(37): 5541-5552, 2007

Analysis of molecular markers and induction of molecular targets in clinical trials with histone deacetylase inhibitors. Proceedings of the American Association for Cancer Research Annual Meeting 44: 190, 2003

The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine. International Journal of Oncology 38(5): 1421-1425, 2011

Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications. Postepy Higieny i Medycyny Doswiadczalnej 67: 722-735, 2014

Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer Journal 13(1): 30-39, 2007

Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?. World Journal of Gastroenterology 19(8): 1173-1181, 2013

Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. International Journal of Biochemistry and Cell Biology 41(1): 16-20, 2008

Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms. International Journal of Molecular Medicine 34(2): 513-532, 2015

Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Molecular Cancer 7: 55, 2008

Molecular basis of histone deacetylase inhibitors as new drugs for the treatment of inflammatory diseases and cancer. Methods in Molecular Biology 512: 365-376, 2009

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clinical Epigenetics 1(3-4): 117-136, 2011

Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. Journal of Pharmacology and Experimental Therapeutics 321(3): 892-901, 2007

P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor. Journal of Nuclear Medicine 55(4): 678-685, 2014